Phase I/II Study Results in 87% Overall Response Rate With Venetoclax, Azacitidine Combo in High-Risk MDS
The use of the BCL-2 inhibitor venetoclax combined with hypomethylating agent azacitidine had encouraging clinical activity in patients with high-risk myelodysplastic syndromes...
Model Helps Predict Use of Single-Agent Romiplostim in Lower-Risk MDS
The phase II EUROPE multicenter trial confirmed that romiplostim is safe and efficacious in a large subset of patients with lower-risk myelodysplastic syndromes...
Luspatercept Improves Anemia After Five Years in Patients With Lower-Risk MDS
Luspatercept therapy for patients with lower-risk myelodysplastic syndromes (MDS), including those with ring sideroblasts (RS) relapsed or refractory to erythropoietin...
Enasidenib Shows Durable Response in IDH2-Mutant MDS
Despite recent progress in the field, treatment for myelodysplastic syndromes (MDS) remains suboptimal. Hypomethylating agents such as azacitidine or decitabine are frontline treatment for ...
Pathogenic Germline Variants Seen in Older Patients With MDS More Frequently Than Expected
This study is the first time that pathogenic or likely pathogenic germline mutations have been examined in patients with MDS across the whole age spectrum who went through related alloHCT...
Hydroxyurea Use Does Not Increase Risk of Secondary Malignancies with MPNs
Despite the mutagenic and leukemogenic potential of hydroxyurea, the current study findings help reaffirm the therapy is safe for older patients...
Cardiovascular Disease and Myeloproliferative Neoplasms
The association between myeloproliferative neoplasms (MPNs) and an increased risk of both thrombotic and hemorrhagic complications has been recognized for some time, ...
Momelotinib Bests Danazol in Symptomatic Patients With Anemic Myelofibrosis
In symptomatic patients with anemia of myelofibrosis (MF), momelotinib was superior to danazol for total symptom score (TSS) response, transfusion independence (TI) rate, and splenic response rate...
SRSF2 Mutation Status May Predict Romiplostim Treatment Response in Lower-Risk MDS
At the time of diagnosis, around half of patients with lower-risk myelodysplastic syndromes (MDS) present with thrombocytopenia, which is associated with shortened survival...
Continuation Trial Confirms Symptom Reduction With Ropeginterferon Alfa-2b Therapy for PV
Researchers confirmed ropeginterferon alfa-2b’s power to effectively reduce symptoms in patients with polycythemia vera...
